IGC Pharma, Inc. (NYSE American: IGC), a clinical-stage pharmaceutical company, has received a Granting Office Action (GOA) from the Divisional Direction of Patents, Mexico, for its Alzheimer's disease treatment titled "Method and Composition for Treating CNS Disorder." The company is optimistic that this success in Mexico could pave the way for additional approvals in the U.S. and Europe.

Presently, IGC Pharma is advancing a Phase 2 trial examining IGC-AD1 as a treatment for agitation in Alzheimer's disease, the most common form of a central nervous system disorder (CNS). IGC-AD1, the lead therapeutic candidate, is a partial CB1 receptor agonist with anti-neuroinflammatory properties designed to address underlying neurodegeneration leading to neuropsychiatric symptoms. The company has strategically sought patent protection for IGC-AD1 in multiple jurisdictions, including the U.S., Europe, Canada, and Mexico. The issuance of the patent for the drug formulation targeting Central Nervous System (CNS) Disorders is considered a significant milestone towards potential commercialization.

Alzheimer's disease is a global public health concern affecting an increasing number of individuals as the population ages. According to the Alzheimer's Association, by 2050, nearly 13 million Americans will be dealing with Alzheimer's, and related costs are expected to reach $1 trillion. The impact extends beyond individuals to families, caregivers, and society, with about 76% of Alzheimer's patients experiencing neuropsychiatric symptoms like agitation.

IGC-AD1 is envisioned to revolutionize Alzheimer's treatment by enhancing the quality of life for millions affected by this devastating disease. The ongoing Phase 2 trial, along with future investigations, aims to validate the effectiveness of IGC-AD1 in managing agitation in Alzheimer's patients and alleviating caregiver burden.

IGC Pharma is actively pursuing five drug assets targeting the treatment of agitation related to Alzheimer's disease symptoms. These assets, including IGC-AD1, TGR-63, LMP, IGC-1C, and IGC-M3, are currently at various stages of clinical trials and development.

 

Source: businesswire.com

Report Abuse